Delix Therapeutics

Delix Therapeutics

Biotechnology, 28 Carlisle Rd, Boston, Massachusetts, 01886, United States, 11-50 Employees

delixtherapeutics.com

  • twitter
  • LinkedIn

Who is DELIX THERAPEUTICS

Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a ...

Read More

map
  • 28 Carlisle Rd, Boston, Massachusetts, 01886, United States Headquarters: 28 Carlisle Rd, Boston, Massachusetts, 01886, United States
  • 2019 Date Founded: 2019
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from DELIX THERAPEUTICS

Delix Therapeutics Org Chart and Mapping

Employees

Colin Frpharms

Vice President - Chemistry, Manufacturing and Controls (Cmc)

Pranay Srivastava

Scientist- Neuroplasticity

Kurt Rasmussen

Chief Scientific Officer

Tyler Wright

IT Project Lead, Consultant

Rebecca D

People Operations Generalist

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Delix Therapeutics

Answer: Delix Therapeutics's headquarters are located at 28 Carlisle Rd, Boston, Massachusetts, 01886, United States

Answer: Delix Therapeutics's official website is https://delixtherapeutics.com

Answer: Delix Therapeutics's revenue is $5 Million to $10 Million

Answer: Delix Therapeutics's SIC: 2834

Answer: Delix Therapeutics's NAICS: 325412

Answer: Delix Therapeutics has 11-50 employees

Answer: Delix Therapeutics is in Biotechnology

Answer: Delix Therapeutics contact info: Phone number: Website: https://delixtherapeutics.com

Answer: Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access